We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current SRPT market cap is 12.06B. The company's latest EPS is USD -5.6112 and P/E is -22.53.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 331.82M | 396.78M | 413.46M | 362.93M | 467.17M |
| Operating Income | -20.84M | 24.63M | 34.91M | -701k | 22.2M |
| Net Income | -40.94M | 45.66M | 36.12M | 6.46M | 33.61M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 380.83M | 540.1M | 701.89M | 933.01M | 1.24B |
| Operating Income | -705.56M | -564.16M | -459.71M | -536.2M | -267.82M |
| Net Income | -715.08M | -554.13M | -418.78M | -703.49M | -535.98M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.11B | 3.26B | 3.22B | 3.42B | 3.6B |
| Total Liabilities | 2.35B | 2.41B | 2.26B | 2.35B | 2.38B |
| Total Equity | 764.36M | 859.34M | 961.19M | 1.08B | 1.22B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.82B | 2.98B | 3.15B | 3.13B | 3.26B |
| Total Liabilities | 1B | 2.22B | 2.22B | 2.74B | 2.41B |
| Total Equity | 818.19M | 761.76M | 928.01M | 384.95M | 859.34M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -446.34M | -500.99M | -242.08M | -227.13M | -297.83M |
| Investing | -101.45M | -165.8M | 218.8M | 120.27M | -8.56M |
| Financing | 123.06M | 125M | 22.14M | 62.06M | 75.82M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -456.46M | 107.47M | -443.17M | -325.35M | -500.99M |
| Investing | 286.73M | -121.72M | 495.41M | -1.05B | -165.8M |
| Financing | 642.55M | 682.32M | 561.57M | 232.51M | 125M |
| Market Cap | 12.06B |
| Price to Earnings Ratio | -22.53 |
| Price to Sales Ratio | 9.71 |
| Price to Cash Ratio | 28.18 |
| Price to Book Ratio | 14.05 |
| Dividend Yield | - |
| Shares Outstanding | 95.52M |
| Average Volume (1 week) | 471.29k |
| Average Volume (1 Month) | 658.86k |
| 52 Week Change | 33.77% |
| 52 Week High | 173.10 |
| 52 Week Low | 91.3439 |
| Spread (Intraday) | 15.4 (11.08%) |
| Company Name | Sarepta Therapeutics Inc New |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.sarepta.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
